Literature DB >> 33919918

Creating Standardized Tools for the Pharmacist-Led Assessment and Pharmacologic Management of Adult Canadians Wishing to Quit Smoking: A Consensus-Based Approach.

Kristi Butt1, Nardine Nakhla1.   

Abstract

Tobacco use continues to be recognized as the single most preventable cause of death worldwide. As the gatekeepers of and experts on pharmacotherapy, pharmacists play a vital role in facilitating smoking cessation. While existing frameworks have enabled pharmacists to provide smoking cessation services in Canada for many years, the way in which they are delivered vary considerably across the nation. The purpose of this initiative was to create standardized tools for the pharmacists providing cessation services to ensure all Canadians wishing to stop smoking have equal access to consistent, evidence-based care. An iterative process using repeated rounds of voting was employed to establish consensus among key opinion leaders on the most important items to include in tools for the pharmacist-led assessment and pharmacologic management of Canadian adults wishing to stop smoking. The results were used to create eight standardized documents for national use by pharmacists: a readiness to quit assessment tool, a patient consent form, a patient assessment form for past users of tobacco and/or tobacco-like products, a patient assessment form for current users of tobacco and/or tobacco-like products, a treatment algorithm, a treatment plan summary form, a prescribing documentation form, and a follow-up & monitoring documentation form. Although not described in detail in these documents, other strategies for smoking cessation (e.g., non-pharmacologic strategies (including quitting "cold turkey" and behavioural interventions), harm reduction strategies, etc.) should be considered when pharmacotherapy is inappropriate or undesired; care should be individualized based on a patient's previous experiences and current motivation. No single approach to treatment is endorsed by the authors. The consensus-based approach described here provides a suggested framework for harmonizing the pharmacist-led management of other ailments to optimize patient care.

Entities:  

Keywords:  community pharmacy; harm reduction; harmonized pharmacist-led care; health prevention; health promotion; non-prescription medicines; over the counter; self-care; smoking cessation; tobacco cessation

Year:  2021        PMID: 33919918     DOI: 10.3390/pharmacy9020080

Source DB:  PubMed          Journal:  Pharmacy (Basel)        ISSN: 2226-4787


  6 in total

1.  Is some provider advice on smoking cessation better than no advice? An instrumental variable analysis of the 2001 National Health Interview Survey.

Authors:  Yuhua Bao; Naihua Duan; Sarah A Fox
Journal:  Health Serv Res       Date:  2006-12       Impact factor: 3.402

2.  Determination and quantification of content validity.

Authors:  M R Lynn
Journal:  Nurs Res       Date:  1986 Nov-Dec       Impact factor: 2.381

Review 3.  Combined pharmacotherapy and behavioural interventions for smoking cessation.

Authors:  Lindsay F Stead; Tim Lancaster
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

Review 4.  Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation.

Authors:  Tamara J Brown; Adam Todd; Claire O'Malley; Helen J Moore; Andrew K Husband; Clare Bambra; Adetayo Kasim; Falko F Sniehotta; Liz Steed; Sarah Smith; Lucie Nield; Carolyn D Summerbell
Journal:  BMJ Open       Date:  2016-02-29       Impact factor: 2.692

5.  Global economic cost of smoking-attributable diseases.

Authors:  Mark Goodchild; Nigar Nargis; Edouard Tursan d'Espaignet
Journal:  Tob Control       Date:  2017-01-30       Impact factor: 7.552

6.  Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology.

Authors:  Breda H Eubank; Nicholas G Mohtadi; Mark R Lafave; J Preston Wiley; Aaron J Bois; Richard S Boorman; David M Sheps
Journal:  BMC Med Res Methodol       Date:  2016-05-20       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.